In recent months, there has been a notable upsurge in the prescription of ivermectin, an antiparasitic drug, particularly among cancer patients, following controversial claims by actor Mel Gibson during a podcast appearance. Gibson suggested that the medication had cured his friends of cancer, a statement that has raised alarm among medical professionals.
:max_bytes(150000):strip_icc():format(jpeg)/Ivermectin-mel-gibson-61826-9e4eb79d2204458390b628573c38e7ce.jpg)
On January 9, 2025, Gibson appeared on “The Joe Rogan Experience,” where he elaborated on the purported success of ivermectin in treating serious ailments. In the podcast, he recounted the stories of three friends who had been diagnosed with stage four cancer but, according to Gibson, are now cancer-free. “There’s got to be something that cures things,” Gibson asserted, implying that ivermectin was the key to their recovery. The enthusiastic endorsement led to a rapid increase in demand for the drug.
Recent research published in the *Journal of the American Medical Association* (JAMA) revealed that prescriptions for ivermectin and the related compound benzimidazole surged by over 160% between 2024 and 2025, a trend largely attributed to Gibson’s podcast claims. The study examined health data from more than 68 million individuals and highlighted significant increases in prescribing patterns, particularly among male patients, and those residing in the southern United States.
However, medical experts have cautioned against the use of ivermectin as a treatment for cancer. Dr. John Mafi, an associate professor of medicine at UCLA, emphasised that there are no conclusive clinical trials validating ivermectin’s efficacy in treating cancer. “It has not been proven in any kind of confirmatory clinical trial, which is the gold standard of evidence we need to know whether treatment works,” he stated.
While ivermectin is recognised as an effective antiparasitic agent, its potential role in oncology is still largely unverified. Benzimidazole, on the other hand, is considered a “promising compound” with some anticancer properties, but further research is required before it can be widely endorsed for cancer treatment.
The situation has raised ethical concerns within the medical community. The JAMA study indicated that the disproportionate increase in ivermectin prescriptions among cancer patients could lead to dire consequences. Individuals battling life-threatening illnesses may opt for unproven therapies, potentially delaying the initiation of effective conventional treatments and allowing their conditions to worsen.
Additionally, there are significant risks associated with the misuse of ivermectin. As Dr Mafi pointed out, taking exceedingly high doses of the drug can result in severe side effects, including seizures or coma, and in rare cases, it could even lead to death. The potential for overdose, especially in desperate patients, adds another layer of seriousness to the issue.
The case of NHL star Ron Duguay, who has also publicly stated that he is incorporating ivermectin into his cancer treatment regimen, further exemplifies the growing trend among individuals seeking unverified treatments. Duguay has expressed his determination to explore every possible avenue in his battle against stage four cancer. “As an athlete, I’m going for it,” he remarked, underlining the desperation many patients feel in their fight against cancer.
The endorsement of ivermectin by high-profile figures like Gibson and Duguay creates a platform that may lead others to follow suit, despite the absence of scientific support. The phenomenon taps into a broader narrative surrounding distrust in traditional medicine, which was exacerbated during the COVID-19 pandemic when ivermectin was promoted as a potential treatment for the virus.
Ultimately, the surge in ivermectin prescriptions represents a complex interplay of celebrity influence, patient desperation, and the quest for effective cancer therapies. As the medical community continues to grapple with these developments, it becomes increasingly crucial to ensure that patients are provided with accurate information and guided towards treatments backed by rigorous scientific evidence.
The ongoing discourse highlights the need for a balanced approach, where personal testimonials do not overshadow the rigorous standards of medical research and practice. The hope remains that patients will prioritise proven treatments on their journey toward recovery, safeguarding their health against unverified claims and the potential repercussions of unregulated medication use.